Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEST: Gemcitabine vs TS-1 vs Combination in Pancreatic Cancer
NCT00498225Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2007
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tegafur in pancreatic cancer (PC) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall Survival. Started Jul 2007; status: completed.
02
Drugs
tegafur
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00498225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498225.